1. Home
  2. MVIS vs CAPR Comparison

MVIS vs CAPR Comparison

Compare MVIS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MicroVision Inc.

MVIS

MicroVision Inc.

HOLD

Current Price

$0.79

Market Cap

271.6M

Sector

Technology

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$25.80

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MVIS
CAPR
Founded
1993
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.6M
1.3B
IPO Year
2010
2011

Fundamental Metrics

Financial Performance
Metric
MVIS
CAPR
Price
$0.79
$25.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$2.50
$41.38
AVG Volume (30 Days)
4.1M
912.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$664,000.00
$22,270,465.00
Revenue This Year
N/A
N/A
Revenue Next Year
$461.65
$17,308.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$4.30
52 Week High
$1.73
$40.37

Technical Indicators

Market Signals
Indicator
MVIS
CAPR
Relative Strength Index (RSI) 47.40 50.85
Support Level $0.65 $25.59
Resistance Level $0.99 $30.06
Average True Range (ATR) 0.06 1.67
MACD 0.01 0.04
Stochastic Oscillator 43.66 52.45

Price Performance

Historical Comparison
MVIS
CAPR

About MVIS MicroVision Inc.

Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: